Home  »  Science   »  Xeris Biopharma Holdings Inc. (NASDAQ: XERS): What...

Xeris Biopharma Holdings Inc. (NASDAQ: XERS): What It’s Worth And What To Do About It

Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s traded shares stood at 1.12 million during the last session, with the company’s beta value hitting 1.31. At the close of trading, the stock’s price was $1.35, to imply an increase of 3.85% or $0.05 in intraday trading. The XERS share’s 52-week high remains $2.95, putting it -118.52% down since that peak but still an impressive 28.15% since price per share fell to its 52-week low of $0.97. The company has a valuation of $189.68M, with an average of 1.22 million shares in intraday trading volume over the past 10 days and average of 1.11 million shares over the past 3 months.

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) trade information

After registering a 3.85% upside in the last session, Xeris Biopharma Holdings Inc. (XERS) has traded red over the past five days. The stock hit a weekly high of 1.3900 this Friday, 03/17/23, jumping 3.85% in its intraday price action. The 5-day price performance for the stock is 11.57%, and 7.14% over 30 days. With these gigs, the year-to-date price performance is 1.50%. Short interest in Xeris Biopharma Holdings Inc. (NASDAQ:XERS) saw shorts transact 6.85 million shares and set a 7.83 days time to cover.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Xeris Biopharma Holdings Inc. (XERS) estimates and forecasts

Looking at statistics comparing Xeris Biopharma Holdings Inc. share performance against respective industry, we note that the company has outperformed competitors. Xeris Biopharma Holdings Inc. (XERS) shares are -24.58% down over the last 6 months, with its year-to-date growth rate higher than industry average at 17.65% against 10.80%. Revenue is forecast to grow 32.00% this quarter before jumping 26.30% for the next one. The rating firms project that company’s revenue will grow 33.20% compared to the previous financial year.

Revenue forecast for the current quarter as set by 3 analysts is $30.76 million. Meanwhile, for the quarter ending Jun 2023, a total of 3 analyst(s) estimate revenue growth to $34.65 million.Earnings reports from the last fiscal year show that sales brought in $22.07 million and $25.31 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 39.40% before jumping 36.90% in the following quarter.

XERS Dividends

Xeris Biopharma Holdings Inc. has its next earnings report out between August 03 and August 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Xeris Biopharma Holdings Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s Major holders

Xeris Biopharma Holdings Inc. insiders hold 2.65% of total outstanding shares, with institutional holders owning 42.54% of the shares at 43.69% float percentage. In total, 42.54% institutions holds shares in the company, led by Stonepine Capital Management, LLC. As of Dec 30, 2022, the company held over 11.2 million shares (or 8.15% of shares), all amounting to roughly $15.11 million.

The next major institution holding the largest number of shares is Blackrock Inc. with 8.58 million shares, or about 6.25% of shares outstanding. As of the market price on Dec 30, 2022, these shares were worth $11.58 million.

We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Xeris Biopharma Holdings Inc. (XERS) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 4.11 million shares. This is just over 3.02% of the total shares, with a market valuation of $5.54 million. Data from the same date shows that the other fund manager holds a little less at 3.06 million, or 2.25% of the shares, all valued at about 4.13 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts